CONICET | Buscador de Institutos y Recursos Humanos

Parkinson?s Disease (PD) is a neurodegenerativeprocess affecting motor function that involves an inflammatory response and Bgroup vitamin deficiencies. Aim: To evaluate the effect of B group vitaminproducing and immunomodulatory lactic acid bacteria (LAB) in murine models ofPD. Methods. Lactobacillus plantarum(Lp) CRL2130, Streptococcus thermophilus(St) CRL808, and Lp CRL1905 (riboflavin, folate and thiamin producers,respectively), and St CRL807 (immunomodulatory strain) were evaluatedindividually or as mixtures using invitro and in vivo PD models. N2aneuronal cells were exposed to the neurotoxin 1-methyl-4-phenylpyridinium (MPP+)in presence of intracellular extracts from vitamin producing LAB. Cellviability and IL-6 production were determined. In vivo, LAB were administered to mice injected with1-meti-l-4-fenil-1,2,3,6-tetrahidropiridina (MPTP). Motor capacity, tyrosinehydroxylase (TH) in brain, and serum and brain cytokines were evaluated.Results: Neurotoxic effect of MPP+ decreased in cells cultured with LABintracellular extracts. This was associated to decreased values of IL-6. Mice givenLAB improved motor tests and increased brain TH+ neurons compared to PD controlgroup. LAB effect was associated to decreased IL-6 and TNF-alpha, and increasedMCP1 in the serum of the mice. MPTP also increased these cytokines locally inmouse?s brains where LAB could also exert benefits. The individual effect ofeach LAB was improved when the mice received the LAB mix demonstrating theimportance of adding different mechanism of action. Conclusions: LAB selectedas B group vitamins producers or as immunomodulators have potential to be usedas immune adjuvants and perhaps as intestinal microbiome modulators against PD

enviar mensaje